



**RNS REACH**

**11 July 2022**

**ImmuPharma PLC**  
("ImmuPharma" or the "Company")

### **INITIATION OF RESEARCH**

ImmuPharma PLC (LSE:IMM), the specialist drug discovery and development company, notes that its joint broker, Stanford Capital Partners ("SCP") has today initiated research coverage on the Company.

The full text of the report can be accessed via SCP's website: [www.stanfordcp.co.uk/research/](http://www.stanfordcp.co.uk/research/) and via Research Tree. Investors are required to self-certify and register in order to access the equity research.

For further information please contact:

**ImmuPharma PLC** ([www.immupharma.com](http://www.immupharma.com)) +44 (0) 207 206 2650

Tim McCarthy, Chairman and Chief Executive Officer

Lisa Baderoon, Head of Investor Relations & Non-Executive Director + 44 (0) 7721 413496

**SPARK Advisory Partners Limited (NOMAD)** +44 (0) 203 368 3550

Neil Baldwin

**Stanford Capital Partners (Joint Broker)** +44 (0) 20 3650 3650

Patrick Claridge, John Howes, Bob Pountney

**SI Capital (Joint Broker)** +44 (0) 1483 413500

Nick Emerson

### **Notes to Editors**

#### **About ImmuPharma PLC**

ImmuPharma PLC (LSE AIM: IMM) is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company's portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives. The lead program, Lupuzor™, is a first-in class autophagy immunomodulator for the treatment of Lupus and preclinical analysis suggest therapeutic activity for many other autoimmune diseases that share the same autophagy mechanism of action.

The new international Phase 3 trial for Lupuzor™ is being funded by Avion, who have the exclusive rights to commercialise Lupuzor™ in the US. The rest of the world rights remain with ImmuPharma and partnering discussions will be an integral part of creating further opportunities for Lupuzor™ in Lupus and the P140 platform across several additional indication targets going forward. The next indication being Chronic inflammatory demyelinating polyneuropathy (CIDP)

For additional information about ImmuPharma please visit [www.immupharma.co.uk](http://www.immupharma.co.uk)

ImmuPharma's LEI (Legal Entity Identifier) code: 213800VZKGHXC7VUS895.

### **About Reach announcements**

Reach is an investor communication service aimed at assisting listed and unlisted (including AIM quoted) companies to distribute media only / non-regulatory news releases such as marketing messages, corporate and product information into the public domain. An RNS Regulatory announcement is required to be notified under the AIM Rules for Companies.